Menu
Back to Journals » Biologics: Targets and Therapy » Volume 1 » Issue 4
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (505)
- Volume 18, 2024 (9)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 1, 2007
Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome
Lars Heslet, Jakob Steen Andersen, Henrik Sengeløv, Björn Dahlbäck, Jorgen Dalsgaard-Nielsen
Biologics: Targets and Therapy 2007, 1:465-472
Published Date: 15 February 2008
The dichloromethane fraction of Stemona tuberosa Lour inhibits tumor cell growth and induces apoptosis of human medullary thyroid carcinoma cells
ZengXia Li, Sonja Sturm, Hermann Stuppner, Elisabeth Schraml, Victor Aguiriano Moser, et al
Biologics: Targets and Therapy 2007, 1:455-463
Published Date: 15 February 2008
Effect of dexamethasone on the IGFBP-1 regulation in premature infants during the first weeks of life
Axel Dost, Eberhard Kauf, Dorothea Schlenvoigt, Dirk Schramm, Felix Zintl, et al
Biologics: Targets and Therapy 2007, 1:449-453
Published Date: 15 February 2008
Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
Peter Valent
Biologics: Targets and Therapy 2007, 1:433-448
Published Date: 15 February 2008
Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS)
David H Dreyfus, S Mark Tompkins, Ramsay Fuleihan, Lucy Y Ghoda
Biologics: Targets and Therapy 2007, 1:425-432
Published Date: 15 February 2008
Tipifarnib in the treatment of acute myeloid leukemia
Xavier Thomas, Mohamed Elhamri
Biologics: Targets and Therapy 2007, 1:415-424
Published Date: 15 February 2008
The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics
Abel D Jarell, Donald Lawrence, Hensin Tsao
Biologics: Targets and Therapy 2007, 1:407-414
Published Date: 15 February 2008
Targeted therapies in the management of metastatic bladder cancer
Matteo Fassan, Edouard J Trabulsi, Leonard G Gomella, Raffaele Baffa
Biologics: Targets and Therapy 2007, 1:393-406
Published Date: 15 February 2008
Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
Madeleine Duvic, Jenny Vu
Biologics: Targets and Therapy 2007, 1:377-392
Published Date: 15 February 2008
Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
John S Vorhies, John J Nemunaitis
Biologics: Targets and Therapy 2007, 1:367-376
Published Date: 15 February 2008
Adalimumab in Crohn's disease
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Biologics: Targets and Therapy 2007, 1:355-365
Published Date: 15 February 2008
Imatinib in the treatment of dermatofibrosarcoma protuberans
Stefanos V Labropoulos, Evangelia D Razis
Biologics: Targets and Therapy 2007, 1:347-353
Published Date: 15 February 2008
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Kristen N Ganjoo, Heather Wakelee
Biologics: Targets and Therapy 2007, 1:335-346
Published Date: 15 February 2008
Targeted therapies in rheumatoid arthritis: Focus on rituximab
YKO Teng, TWJ Huizinga, JM van Laar
Biologics: Targets and Therapy 2007, 1:325-333
Published Date: 15 February 2008